Intrathecal Zolgensma Delay Could Allow Competitors To Shine
US FDA Requests Confirmatory Clinical Study
The rollercoaster ride continues for Novartis’s gene therapy Zolgensma, with the company committing to providing further clinical data on an intrathecal formulation for older spinal muscular atrophy patients.
